Oncolytics signs deal with NCIC CTG for Reolysin s Oncolytics signs deal with NCIC CTG for Reolysin study
Oncolytics Biotech Inc (C:ONC)
Shares Issued 76,317,085
Last Close 2/17/2012 $4.94
Tuesday February 21 2012 - News Release
Dr. Brad Thompson reports
ONCOLYTICS BIOTECHATRADEMARK INC. ENTERS INTO SPONSORSHIP AGREEMENT WITH NCIC CTG FOR RANDOMIZED PHASE II STUDY IN PROSTATE CANCER
Oncolytics Biotech Inc. has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ont., will sponsor and conduct a randomized phase 2 study of Reolysin in patients with recurrent or metastatic castration resistant prostate cancer.
"Third party sponsored trials remain an important part of our overall clinical strategy. We are pleased to be conducting another randomized study, especially in Canada, with an experienced and capable group like the NCIC CTG," said Dr. Brad Thompson, President and CEO of Oncolytics. "This study will build on both our early preclinical and clinical prostate cancer work, as well as our growing understanding of REOLYSIN in combination with approved chemotherapeutic agents. As a Company we continue to expand our clinical program to include studies of frequently diagnosed cancers."
The study will be an open-label, randomized, non-blinded, Phase II clinical study of REOLYSIN given in combination with docetaxel versus docetaxel alone. Approximately 40 response evaluable patients will be enrolled in each arm.
About Prostate Cancer
The Canadian Cancer Society estimates that 25,500 Canadians were diagnosed with prostate cancer and nearly 4,100 Canadians were expected to die from the disease in 2011. The prognosis for patients diagnosed with prostate cancer varies but the five-year survival rate for the period between 2004 and 2006 was approximately 95%.
About the NCIC Clinical Trials Group at Queen's University
The NCIC Clinical Trials Group (NCIC CTG) is a cancer clinical trials cooperative group that conducts Phase I-III trials testing anti-cancer and supportive therapies across Canada and internationally. It is a national research program of the Canadian Cancer Society. The NCIC CTG's Central Office is located at Queen's University in Kingston, Ontario, Canada. The Group is committed to assessing all modalities of therapy for a spectrum of cancer types. More than 60 member institutions, from major cancer centres to community hospitals, enroll patients in NCIC Clinical Trials Group studies.
We seek Safe Harbor.
© 2012 Canjex Publishing Ltd.